Documents Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO,...

Slide 1 Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy…

Documents Presented By Mario Sznol at 2014 ASCO Annual Meeting

Slide 1 Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy…

Documents Yale Cancer Center CenterPoint Magazine Spring | Summer 2014

spring | summer 2014 From Bench to Bedside and Back 2 What if you were the patient? Clinicians redesign care. 4 From Bench to Bedside and Back The rallying cry at Yale Cancer…

Documents Breakthroughs > The Year in Review 2014

yale cancer center Thomas J. Lynch, Jr., MD Director Kevin Vest, MBA, FACHE Deputy Director, Administration and Clinical Affairs Renee Gaudette Director, Public Affairs and…